Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390284 · ClinicalTrials.gov registry record · Phase 3
Stop Retinal Ganglion Cell Dysfunction Study
A Phase 3 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
NCT02390284: Clinical Trial Phase 3 study, sponsored by University of Miami.
NCT02390284 is a Phase 3 study that was terminated before completion, run by University of Miami. The registered enrollment target is 28 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02390284, a Phase 3 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
Study Summary
Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease, predicting its severity and the benefit of pressure lowering eye drops is key to clinical management aimed at maintaining useful vision with advancing age. This study will longitudinally monitor a population of glaucoma suspects (with positive factors for the disease but with normal vision) with noninvasive pattern electroretinogram (PERG) and other standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells (RGCs) that are the parent neurons of the optic nerve. RGCs may become dysfunctional before dying and their function restored with pressure-lowering eye drops. Glaucoma suspects with abnormal PERG will be randomized to treatment with eye drops, while those with normal PERG will be left untreated. All patients will be monitored with PERG, Optic Coherence Tomography (OCT) and other ancillary tests every 6 months over 4 years.
Primary Outcome
As measured by Optical Coherence Tomography in different timepoints as an absolute value in micrometers.
Interventions
- DRUG Bimatoprost
- DRUG Latanoprost
- DRUG Dorzolamide
- DRUG Timolol
- DRUG Travoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-09 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 3 |
Why NCT02390284 stopped before completion
NCT02390284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which Bimatoprost is the first listed.
NCT02390284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02390284 about?
NCT02390284 is a clinical study titled "Stop Retinal Ganglion Cell Dysfunction Study". Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease, predicting its severity and the benefit of pressure lowering eye drops is key to clinical management aimed at maintaining useful vision with advancing age. This study will longitudinally monitor a populat...
What is the current status of trial NCT02390284?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2015-09. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT02390284?
The interventions under investigation include: Bimatoprost (DRUG), Latanoprost (DRUG), Dorzolamide (DRUG), Timolol (DRUG), Travoprost (DRUG).
Who is sponsoring clinical trial NCT02390284?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02390284's enrollment target sits among peer trials
28 1935th of 2000 higher than 65 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia